Efficacy and safety of neural stem cell therapy for spinal cord injury: A systematic literature review
Autor: | Rohit Rajak, Santosh K. Tiwari, Asma Sultana, Shaik Abjal Pasha, Aleem Ahmed Khan, Varun Kumar Sharma, Divya Gauba, Yugandhar P. Reddy, Shiva V. Kumar, Pinaki Ghosh, Shaswati Khan, Aishwarya Kulkarni, Tanu Khurana |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
business.industry American Spinal Injury Association Pain Cochrane Library medicine.disease 030226 pharmacology & pharmacy Neural stem cell law.invention 03 medical and health sciences 0302 clinical medicine Systematic review Study Eligibility Criteria Randomized controlled trial Neural Stem Cells law medicine Physical therapy Humans Pharmacology (medical) Prospective Studies business Spinal cord injury Motor score Spinal Cord Injuries |
Zdroj: | Therapie. 76(3) |
ISSN: | 1958-5578 |
Popis: | To summarize the evidence on the efficacy and safety of neural stem cell therapy (NSCT) for the treatment of spinal cord injury (SCI).A systematic literature review of Medline®, EMBASE® and Cochrane library was performed to identify studies reporting efficacy and safety of NSCT in SCI. Articles were included if they reported efficacy and safety data of SCI patients who received NSCT.Overall, four studies of the 277 records met all the study eligibility criteria. Over the 1-year follow-up period, motor scores were significantly higher among patients who received NSCT compared with those who did not (American Spinal Injury Association [ASIA] motor scores (mean±standard deviation [SD]): 7.9±1.2 versus 3.9±0.6; upper extremity motor score: 7.8±2.1 versus 3.9±0.6, both P0.05). Sensory scores (pinprick score: 4.8±1.3 versus 2.9±0.6; P=0.5; light touch score: 6.9±3.1 versus 2.3±0.5, P=0.3), ASIA impairment scale (26% versus 7%) or pain score (baseline: 2.4±0.6; 1-year: 3.4±0.4) were comparable in both NSCT and non-NSCT cohorts. Over the 1-year follow-up period, the graded redefined assessment of strength, sensibility, and prehension and international standards for neurological classification of SCI scores showed a mean improvement of 14.8 and 17.8 points respectively. Overall, treatment with NSCT showed favorable safety and tolerability profile.Due to the limited and poor-quality evidence, it is too early to make robust conclusions on the efficacy of NSCT in the treatment of SCI. However, based on the included studies, NSCT seems to be a potential option worth exploring among patients with SCI. Nonetheless, prospective, randomized trials in larger cohorts are needed to validate the efficacy and safety of NSCT in the treatment of SCI. |
Databáze: | OpenAIRE |
Externí odkaz: |